Dr Reddy’s

Buy Dr Reddy’s Labs With Stoploss Of Rs 785: Hitendra Vasudeo

Buy Dr Reddy’s Labs With Stoploss Of Rs 785: Hitendra VasudeoStock market analyst Hitendra Vasudeo of stockmechanics.com maintained ‘Buy’ rating on Dr Reddy’s Labs to achieve an intraday target of Rs 815.

According to Mr. Vasudeo, interested traders can buy the stock around Rs 800-Rs 790 with a strict stop loss of Rs 785.

Mr. Vasudeo also said that if the stock market remains on the positive track, the stock will hit another target of Rs 830 in today’s session.

Buy Dr Reddy's Labs With Stoploss Of Rs 718: Ashwani Gujral

 Buy Dr Reddys Labs With Stoploss Of Rs 718: Ashwani GujralStock market analyst Ashwani Gujral has maintained ‘Buy’ rating on Dr Reddy`s Laboratories to achieve a target between Rs 765- Rs 800 in 1-2 trading sessions.

According to Mr. Gujral, interested traders can buy the stock with a strict stop loss of Rs 718.

The shares of the company, on Tuesday (June 20), closed at Rs 743.65 on the Bombay Stock Exchange (BSE). Current EPS and P/E of the stock stood at 33.29 & 22.54 respectively. The share price has seen a 52-week high of Rs 764 and a low of Rs 357 on BSE.

Dr Reddy’s launches ‘Tablet Solifencin Succinate’ in India

Dr Reddy’s launches ‘Tablet Solifencin Succinate’ in IndiaGlobal drug maker Dr Reddy's Laboratories has announced the launch of Tablet Bispec (solifenacin succinate) in domestic market.

The company claims that Bispec is the best-in-class drug in its segment and has lesser incidence of dry mouth and constipation.

The drug is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The newly launched drug will be available in tablet form, and in dosages of 5 mg and 10 mg.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content